[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Saha et al., 2014 - Google Patents

Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer

Saha et al., 2014

View HTML
Document ID
8040398574667632281
Author
Saha S
Parachoniak C
Ghanta K
Fitamant J
Ross K
Najem M
Gurumurthy S
Akbay E
Sia D
Cornella H
Miltiadous O
Walesky C
Deshpande V
Zhu A
Hezel A
Yen K
Straley K
Travins J
Popovici-Muller J
Gliser C
Ferrone C
Apte U
Llovet J
Wong K
Ramaswamy S
Bardeesy N
Publication year
Publication venue
Nature

External Links

Snippet

Mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 are among the most common genetic alterations in intrahepatic cholangiocarcinoma (IHCC), a deadly liver cancer,,,,. Mutant IDH proteins in IHCC and other malignancies acquire an abnormal enzymatic activity …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Similar Documents

Publication Publication Date Title
Saha et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer
Wang et al. N 1-methyladenosine methylation in tRNA drives liver tumourigenesis by regulating cholesterol metabolism
Wu et al. Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p
Sun et al. Modelling liver cancer initiation with organoids derived from directly reprogrammed human hepatocytes
Yuan et al. NUAK2 is a critical YAP target in liver cancer
Lu et al. Activation of NRF2 ameliorates oxidative stress and cystogenesis in autosomal dominant polycystic kidney disease
Gay et al. Loss of BCL9/9l suppresses Wnt driven tumourigenesis in models that recapitulate human cancer
Fox et al. Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma
Kim et al. RORα controls hepatic lipid homeostasis via negative regulation of PPARγ transcriptional network
Wang et al. SOD1 regulates ribosome biogenesis in KRAS mutant non-small cell lung cancer
Zhang et al. Hepatic HuR modulates lipid homeostasis in response to high-fat diet
Nelson et al. Inhibition of hepatic lipogenesis enhances liver tumorigenesis by increasing antioxidant defence and promoting cell survival
Luo et al. Hepatocyte nuclear factor 1A (HNF1A) as a possible tumor suppressor in pancreatic cancer
To et al. Kras regulatory elements and exon 4A determine mutation specificity in lung cancer
Han et al. Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma
Fu et al. A ZEB1/p53 signaling axis in stromal fibroblasts promotes mammary epithelial tumours
Calvisi et al. Forkhead box M1B is a determinant of rat susceptibility to hepatocarcinogenesis and sustains ERK activity in human HCC
Jin et al. ALDH2 (E487K) mutation increases protein turnover and promotes murine hepatocarcinogenesis
Xu et al. Mettl3-mediated mRNA m6A modification controls postnatal liver development by modulating the transcription factor Hnf4a
Holt et al. Activation of apoptosis in NAF-1-deficient human epithelial breast cancer cells
Sekine et al. Dicer is required for proper liver zonation
Yang et al. GSTZ 1‐1 Deficiency Activates NRF 2/IGF 1R Axis in HCC via Accumulation of Oncometabolite Succinylacetone
Jiang et al. Sodium new houttuyfonate suppresses metastasis in NSCLC cells through the Linc00668/miR-147a/slug axis
Lin et al. TR4 nuclear receptor functions as a tumor suppressor for prostate tumorigenesis via modulation of DNA damage/repair system
Chou et al. Ribose-5-phosphate isomerase A overexpression promotes liver cancer development in transgenic zebrafish via activation of ERK and β-catenin pathways